Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) will announce its third quarter 2022 financial results on October 27, 2022, followed by an investor conference call at 8:30 a.m. ET. Shareholders can access the call at (844) 200-6205 (U.S.) or (929) 526-1599 (international), using access code 889963. A replay will be available for two hours post-call, lasting until November 26, 2022. Insmed focuses on therapies for serious and rare diseases, with its first product approved in multiple markets, including the U.S., Europe, and Japan.

Positive

• Insmed's first commercial product is approved in the U.S., Europe, and Japan, targeting chronic lung disease.
• The company has a robust pipeline of therapies addressing serious unmet medical needs.

Negative

• None.

BRIDGEWATER, N.J., Oct. 13, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2022 financial results on Thursday, October 27, 2022.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 27, 2022 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international) and referencing access code 889963. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 2 hours after its completion through November 26, 2022, by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 035584. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2022-financial-results-conference-call-on-thursday-october-27-2022-301643047.html

SOURCE Insmed Incorporated

FAQ

When will Insmed release its third quarter 2022 financial results?

Insmed will release its third quarter 2022 financial results on October 27, 2022.

What time is the Insmed conference call for the third quarter results?

The conference call will begin at 8:30 a.m. ET on October 27, 2022.

How can I participate in the Insmed conference call?

To participate, dial (844) 200-6205 for U.S. callers or (929) 526-1599 for international callers and use access code 889963.

Will there be a replay of the Insmed conference call?

Yes, a replay will be available approximately two hours after the call and accessible until November 26, 2022.

What is Insmed's mission?

Insmed is focused on transforming the lives of patients with serious and rare diseases.